Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice,Allergy

当前位置： X-MOL 学术 › Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice
Allergy ( IF 12.6 ) Pub Date : 2021-05-06 , DOI: 10.1111/all.14879
Shinji Toki ₁ , Dawn C Newcomb _{1,

2} , Richard L Printz ₃ , Katherine N Cahill ₁ , Kelli L Boyd ₂ , Kevin D Niswender _{3,

4,

5} , R Stokes Peebles _{1,

2,

5}

Affiliation

Obesity is a risk factor for the development of asthma. However, pharmacologic therapeutic strategies that specifically target obese asthmatics have not been identified. We hypothesize that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment inhibits aeroallergen-induced early innate airway inflammation in a mouse model of asthma in the setting of obesity.

中文翻译：

胰高血糖素样肽 1 受体激动剂抑制肥胖小鼠中空气过敏原诱导的 ILC2 激活和中性粒细胞气道炎症

肥胖是哮喘发生的危险因素。然而，尚未确定专门针对肥胖哮喘患者的药物治疗策略。我们假设，在肥胖小鼠哮喘模型中，胰高血糖素样肽 1 受体激动剂 (GLP-1RA) 治疗可抑制空气过敏原诱导的早期先天性气道炎症。

更新日期：2021-05-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南